Authors

Latest:

Insights from ARTEMIS-001

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

Aaron LeBeau, PhD

Latest:

Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate Cancer

Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.

Noah Kalman, MD, MBA

Latest:

Tumor-Killing Technology in Head and Neck Cancer

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Jorge Nieva, MD

Latest:

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Thomas Bachelot, MD, PhD

Latest:

Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases

Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.

Radhika Bansal, MBBS

Latest:

Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

Ruth O'Regan, MD, University of Rochester Medical Center

Latest:

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Ben Levy, MD, The Johns Hopkins University School of Medicine

Latest:

Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

Jameel Muzaffar, MD

Latest:

Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCC

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.

James Hoffman, MD, University of Miami Sylvester Cancer Center

Latest:

What’s Coming Next in Relapsed/Refractory Multiple Myeloma

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Paul Bunn, MD, University of Colorado Cancer Center

Latest:

The Impact of Chemotherapy-Induced Myelosuppression

Paul C. Boutros, PhD, MBA

Latest:

Dr. Boutros on the Utility of Genetic Testing in Prostate Cancer

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Michael Iglesia, MD, PhD

Latest:

Dr Iglesia on the Potential Role for Disease Etiology in Frontline HCC Treatment Selection

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

Thomas Westbrook, MD

Latest:

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Vikas S. Ostwal, MD

Latest:

Dr Ostwal on T-DM1 in Pretreated HER2+ Advanced Biliary Tract Cancer

Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.

Geoffrey L. Uy, MD

Latest:

Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AML

Geoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.

Andrew Brunner, MD

Latest:

Closing Thoughts on the MDS Treatment Landscape

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Mark Christopher Markowski, MD, PhD

Latest:

Dr. Markowski on the Evaluation of Sabizabulin in mCRPC

Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication

Latest:

CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Saum Ghodoussipour, MD

Latest:

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.